EUCTR2009-012151-23-GB进行中（未招募）1 期
A randomised phase II study of Irinotecan, 5-Fluorouracil and Folinic Acid (FOLFIRI) with or without the addition of an endothelin receptor antagonist in patients with metastatic colorectal cancer after failure of Oxaliplatin-containing chemotherapy - FOLFIRI plus ZD4054 in colorectal cancers refractory to oxaliplatin
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 122
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Patients meeting all of the following criteria may be included in the trial:
- •1)Histological or cytological diagnosis of metastatic colorectal cancer.
- •2)Patients must be resistant to oxaliplatin. If metastatic patients progress at any time after oxaliplatin containing chemotherapy, or if adjuvant patients progress within 6 months of oxaliplatin containing chemotherapy they will be included in this study providing that they have no significant ongoing toxicity (excluding grade 1 neurotoxicity)
- •3)Measurable disease by RECIST criteria.
- •4)Adequate bone marrow, hepatic and renal function including the following:
- •a)Haemoglobin = 9.0 g/L (no prior transfusion) or = 10.0 g/L (transfusion within last 4 weeks), absolute neutrophil count = 1.5 x 109/L, platelets =100 x 109/L;
- •b)Total bilirubin < 1.5 x upper normal limit;
- •c)AST and ALT = 2.5 x upper normal limit (or = 5x UNL in the presence of liver metastases);
- •d)Creatinine clearance (as measured by Cockcroft and Gault equation, appendix 2) =50mls/min.
- •5)Age = 18 years.
- •6)ECOG Performance status 0 or 1.
- •7)Patients must have recovered from effects of major surgery.
- •8)In view of concerns of possible teratogenicity, female patients must have no child bearing potential. A negative urine or serum pregnancy test within 3 days prior to start of trial treatment is required. A pregnancy test is not necessary for women who are post-menopausal.
- •9)Males with reproductive potential should be prepared to use adequate contraception
- •10)Life expectancy of at least 12 weeks.
- •11)The patient has provided written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •If any of the following criteria apply, patients cannot be included in the trial:
- •1)Any chemotherapy, radiotherapy (except for palliative reasons), endocrine therapy or immunotherapy within four weeks prior to commencing treatment. Patients may continue the use of corticosteroids provided the dose is stable for 4 weeks and not altered during the first 15 days of the study.
- •2)Have received more than one course of chemotherapy for metastatic disease, and any previous treatment with ZD4054 or Irinotecan. Where oxaliplatin has been used in an intermittent schedule allowing patient holidays, it will be considered equivalent to one prior line of therapy providing that patients have had at least stable disease whilst on active treatment.
- •3)Extensive prior irradiation (likely to deplete bone marrow reserve).
- •4)Major surgery within 4 weeks of starting the study.
- •5)Co-existing active infection or serious concurrent medical condition.
- •6)Significant cardiovascular disease as defined by:
- •a)history of congestive heart failure requiring therapy (NYHA grade 2 or higher);
- •b)history of unstable angina pectoris or myocardial infarction up to 6 months prior to trial entry;
- •c)presence of severe valvular heart disease;
- •d)presence of a ventricular arrhythmia requiring treatment.
- •e)Prolonged QTc interval, >470msec.
- •7)Any co-existing medical condition that in the investigator’s judgement will substantially increase the risk associated with the patient’s participation in the study or potentially hamper compliance with the study protocol and follow-up schedule.
- •8)Psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or compliance with the study protocol.
- •9)Bone metastases.
- •10)Known brain or leptomeningeal metastases unless patients have stable disease following surgical resection or radiosurgery of oligometastases.
- •11)Gastrointestinal disorders likely to interfere with absorption of the study drug (e.g. partial bowel obstruction or malabsorption).
- •12)Patients known to be serologically positive for Hepatitis B or Hepatitis C (mandatory testing not required).
- •13)Immunocompromised patients e.g. patients who are known to be serologically positive for human immunodeficiency virus (HIV) (mandatory testing not required).
- •14)Women of childbearing potential who are pregnant or breast-feeding. Women of childbearing potential are defined as sexually mature women who have not undergone a hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive months (i.e., who have had menses any time in the preceding 12 consecutive months). Women of childbearing potential must have a negative serum pregnancy test = 3 days prior to starting study treatment.
- •15)Other previous or current malignant disease likely to interfere with protocol treatment or comparisons.
研究者
相似试验
已完成
2 期
Fluorouracil and folinic acid (FOLFIRI) plus an endothelin receptor antagonist (ERAT) in advanced colorectal cancer patients who have failed on oxaliplatin-containing chemotherapyocally advanced and/or metastatic colorectal cancer (mCRC)Malignant neoplasm of rectosigmoid junctionCancerISRCTN73199181Cardiff University (UK)122
已完成
2 期
A Phase II Trial Evaluating Irinotecan Plus 5FU/LV in Patients With Relapsed/Refractory Upper GI TumoursUpper Gastrointestinal TumoursNCT00220064Royal Marsden NHS Foundation Trust65
进行中（未招募）
1 期
Combination of Nal-IRI and 5-Fluorouracil compared to 5-Fluorouracil alone in patients with cholangio- and gallbladder cancer previously treated with gemcitabine-based therapiesadvanced, unresectable and metastatic cholangio- and gallbladder carcinomaMedDRA version: 20.0Level: PTClassification code 10008593Term: CholangiocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10077846Term: Cholangiocarcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLTClassification code 10017634Term: Gallbladder neoplasms malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10051667Term: Metastases to gallbladderSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10017614Term: Gallbladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-003709-33-DEAIO-Studien-gGmbH100
进行中（未招募）
不适用
A clinical trial to compare tolerabilty and efficiacy (how well the drug works) of following treatments:Blocking liver arteries (chemoembolisation) by beads loaded with irinotecan (chemotherapeutic) and intravenous administration of cetuximab (chemotherapeutic) compared to administration of intravenous cetuximab and irinotecan in patients with k-ras (gene) wild-type tumors.Patients with unresectable liver metastases of colorectal cancer who previously failed pretreatment with 5FU/oxaliplatin and/or 5FU/irinotecan (2nd- or 3rd-line).MedDRA version: 14.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-014728-44-DEMartin Luther Universität Halle-Wittenberg80
已完成
2 期
Phase II CPT-11, LV and 5FU in Gastric CancerCancer - StomachGastric CancerACTRN12605000706673Site - Investigator Initiated . AGITG sponsored trial, conducted through NHMRC CTC80